 Jun Ying
Concepts (287)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 8 | 2021 | 2674 | 1.280 |
Why?
| | Folic Acid | 1 | 2023 | 197 | 0.700 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1709 | 0.640 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 2 | 2019 | 1194 | 0.600 |
Why?
| | Diabetes, Gestational | 1 | 2023 | 307 | 0.590 |
Why?
| | Platinum Compounds | 1 | 2019 | 10 | 0.590 |
Why?
| | ErbB Receptors | 3 | 2019 | 636 | 0.590 |
Why?
| | Fixatives | 1 | 2019 | 13 | 0.580 |
Why?
| | Genes, erbB | 1 | 2018 | 2 | 0.580 |
Why?
| | Desiccation | 1 | 2019 | 26 | 0.570 |
Why?
| | Indicators and Reagents | 1 | 2019 | 105 | 0.570 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2021 | 627 | 0.560 |
Why?
| | Proteoglycans | 1 | 2019 | 111 | 0.550 |
Why?
| | Neoplasm Proteins | 2 | 2019 | 443 | 0.550 |
Why?
| | Serum Albumin | 1 | 2019 | 147 | 0.550 |
Why?
| | Circulating Tumor DNA | 1 | 2018 | 50 | 0.540 |
Why?
| | Fibrinogen | 1 | 2019 | 181 | 0.530 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 226 | 0.480 |
Why?
| | Pneumonia | 2 | 2019 | 633 | 0.470 |
Why?
| | Immunotherapy | 1 | 2021 | 669 | 0.470 |
Why?
| | Mitochondria | 1 | 2023 | 996 | 0.460 |
Why?
| | Biopsy | 1 | 2019 | 1073 | 0.440 |
Why?
| | Bone Neoplasms | 1 | 2017 | 271 | 0.420 |
Why?
| | Adenocarcinoma | 2 | 2019 | 927 | 0.410 |
Why?
| | Insulin Resistance | 1 | 2023 | 1247 | 0.410 |
Why?
| | Respiration, Artificial | 1 | 2019 | 711 | 0.390 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 889 | 0.380 |
Why?
| | Biomarkers, Tumor | 3 | 2019 | 1334 | 0.350 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 926 | 0.330 |
Why?
| | Breast Neoplasms | 1 | 2023 | 2411 | 0.310 |
Why?
| | Lymphatic Metastasis | 2 | 2023 | 335 | 0.300 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2019 | 333 | 0.290 |
Why?
| | Genes, Bacterial | 2 | 2020 | 151 | 0.270 |
Why?
| | Neoplasms | 2 | 2024 | 2944 | 0.260 |
Why?
| | Humans | 31 | 2024 | 145625 | 0.250 |
Why?
| | Sensitivity and Specificity | 5 | 2018 | 1992 | 0.250 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 387 | 0.220 |
Why?
| | Coronavirus Infections | 2 | 2020 | 379 | 0.220 |
Why?
| | Neurofeedback | 1 | 2024 | 5 | 0.210 |
Why?
| | Receptors, Purinergic P2X7 | 1 | 2023 | 12 | 0.200 |
Why?
| | Female | 17 | 2024 | 79080 | 0.200 |
Why?
| | Mendelian Randomization Analysis | 1 | 2024 | 68 | 0.200 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 36 | 0.200 |
Why?
| | Arrestins | 1 | 2023 | 14 | 0.190 |
Why?
| | Emergence Delirium | 1 | 2023 | 7 | 0.190 |
Why?
| | Astrocytes | 2 | 2023 | 229 | 0.190 |
Why?
| | Glycyrrhiza uralensis | 1 | 2023 | 1 | 0.190 |
Why?
| | Eucommiaceae | 1 | 2023 | 1 | 0.190 |
Why?
| | Thiamphenicol | 3 | 2020 | 3 | 0.190 |
Why?
| | Graphite | 1 | 2022 | 14 | 0.190 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2023 | 38 | 0.190 |
Why?
| | Radiation Oncology | 1 | 2023 | 83 | 0.190 |
Why?
| | Virtual Reality | 1 | 2024 | 82 | 0.180 |
Why?
| | Delirium | 1 | 2024 | 106 | 0.180 |
Why?
| | Interleukin-33 | 1 | 2022 | 45 | 0.180 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2022 | 11 | 0.180 |
Why?
| | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 27 | 0.180 |
Why?
| | Drug Resistance, Multiple, Bacterial | 2 | 2020 | 77 | 0.180 |
Why?
| | Neurodegenerative Diseases | 1 | 2024 | 147 | 0.170 |
Why?
| | Rectal Neoplasms | 1 | 2023 | 159 | 0.170 |
Why?
| | Neuroglia | 1 | 2022 | 176 | 0.170 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2022 | 588 | 0.170 |
Why?
| | Mutation | 4 | 2023 | 4082 | 0.170 |
Why?
| | Aged | 6 | 2024 | 26251 | 0.160 |
Why?
| | Colonic Neoplasms | 1 | 2023 | 257 | 0.160 |
Why?
| | Mitochondrial Proteins | 1 | 2023 | 263 | 0.160 |
Why?
| | Keloid | 1 | 2020 | 8 | 0.160 |
Why?
| | Middle Aged | 9 | 2024 | 36359 | 0.160 |
Why?
| | Genotype | 2 | 2023 | 1866 | 0.160 |
Why?
| | Convalescence | 1 | 2020 | 19 | 0.160 |
Why?
| | Proteus | 1 | 2020 | 4 | 0.160 |
Why?
| | Proteus Infections | 1 | 2020 | 5 | 0.160 |
Why?
| | Central Nervous System | 1 | 2022 | 278 | 0.150 |
Why?
| | Honey | 2 | 2010 | 11 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2024 | 1125 | 0.150 |
Why?
| | Osteoarthritis, Knee | 1 | 2023 | 284 | 0.150 |
Why?
| | Tandem Mass Spectrometry | 1 | 2022 | 574 | 0.150 |
Why?
| | Smartphone | 1 | 2020 | 103 | 0.150 |
Why?
| | Nucleic Acids | 1 | 2020 | 73 | 0.150 |
Why?
| | Genome, Bacterial | 1 | 2020 | 122 | 0.140 |
Why?
| | Dietary Supplements | 1 | 2023 | 586 | 0.140 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2019 | 9 | 0.140 |
Why?
| | Ultrasonics | 1 | 2019 | 50 | 0.140 |
Why?
| | Plasmids | 1 | 2020 | 372 | 0.140 |
Why?
| | Homeostasis | 1 | 2023 | 646 | 0.140 |
Why?
| | Formaldehyde | 1 | 2019 | 65 | 0.140 |
Why?
| | Liquid Biopsy | 1 | 2018 | 16 | 0.140 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 745 | 0.140 |
Why?
| | Male | 12 | 2024 | 73014 | 0.140 |
Why?
| | Scleroderma, Systemic | 1 | 2019 | 123 | 0.140 |
Why?
| | DNA, Neoplasm | 1 | 2019 | 160 | 0.140 |
Why?
| | Synapses | 1 | 2022 | 447 | 0.140 |
Why?
| | Cytodiagnosis | 1 | 2018 | 31 | 0.140 |
Why?
| | Biopsy, Fine-Needle | 1 | 2018 | 79 | 0.140 |
Why?
| | Glucose | 1 | 2023 | 1051 | 0.130 |
Why?
| | Interferons | 1 | 2019 | 186 | 0.130 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2020 | 189 | 0.130 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 191 | 0.130 |
Why?
| | Neoadjuvant Therapy | 1 | 2021 | 474 | 0.130 |
Why?
| | DNA Mutational Analysis | 1 | 2019 | 409 | 0.130 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 538 | 0.130 |
Why?
| | Transcription Factors | 2 | 2023 | 1728 | 0.130 |
Why?
| | Procollagen | 1 | 2017 | 24 | 0.130 |
Why?
| | Gene Rearrangement | 1 | 2018 | 155 | 0.130 |
Why?
| | Workflow | 1 | 2019 | 181 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.130 |
Why?
| | Disease-Free Survival | 1 | 2019 | 777 | 0.130 |
Why?
| | Alzheimer Disease | 1 | 2023 | 640 | 0.120 |
Why?
| | Bone Remodeling | 1 | 2017 | 71 | 0.120 |
Why?
| | ROC Curve | 1 | 2019 | 613 | 0.120 |
Why?
| | Cisplatin | 1 | 2019 | 346 | 0.120 |
Why?
| | Peptides | 1 | 2023 | 991 | 0.120 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 144 | 0.120 |
Why?
| | Feces | 1 | 2020 | 494 | 0.120 |
Why?
| | Collagen Type I | 1 | 2017 | 144 | 0.120 |
Why?
| | beta-Lactamases | 1 | 2016 | 54 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 959 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 578 | 0.120 |
Why?
| | Phycocyanin | 1 | 2015 | 4 | 0.120 |
Why?
| | Spirulina | 1 | 2015 | 4 | 0.120 |
Why?
| | Temperature | 1 | 2019 | 633 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 767 | 0.110 |
Why?
| | Myostatin | 1 | 2015 | 24 | 0.110 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1318 | 0.110 |
Why?
| | Homocysteine S-Methyltransferase | 1 | 2015 | 5 | 0.110 |
Why?
| | Gene Knockout Techniques | 1 | 2015 | 122 | 0.110 |
Why?
| | Macrophages | 1 | 2023 | 1530 | 0.110 |
Why?
| | Gene Transfer, Horizontal | 1 | 2015 | 34 | 0.110 |
Why?
| | Colorectal Neoplasms | 1 | 2023 | 870 | 0.110 |
Why?
| | Escherichia coli Proteins | 1 | 2016 | 200 | 0.110 |
Why?
| | Phylogeny | 2 | 2016 | 921 | 0.100 |
Why?
| | Prospective Studies | 4 | 2023 | 8087 | 0.100 |
Why?
| | CRISPR-Cas Systems | 1 | 2015 | 163 | 0.100 |
Why?
| | Dogs | 1 | 2015 | 516 | 0.100 |
Why?
| | Cognition | 1 | 2022 | 1286 | 0.100 |
Why?
| | Vitamin D | 1 | 2017 | 402 | 0.100 |
Why?
| | Neutrophils | 1 | 2019 | 1132 | 0.100 |
Why?
| | Calixarenes | 1 | 2013 | 5 | 0.100 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 1 | 2013 | 15 | 0.100 |
Why?
| | Angiopoietin-2 | 1 | 2013 | 15 | 0.100 |
Why?
| | Peptide Fragments | 1 | 2017 | 693 | 0.100 |
Why?
| | Uterine Hemorrhage | 1 | 2013 | 41 | 0.090 |
Why?
| | Databases, Factual | 1 | 2019 | 1481 | 0.090 |
Why?
| | Internship and Residency | 1 | 2023 | 1269 | 0.090 |
Why?
| | Transcriptome | 1 | 2019 | 1066 | 0.090 |
Why?
| | Phenols | 1 | 2013 | 106 | 0.090 |
Why?
| | Escherichia coli | 1 | 2016 | 831 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2020 | 11744 | 0.090 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 982 | 0.090 |
Why?
| | Organometallic Compounds | 1 | 2013 | 110 | 0.090 |
Why?
| | Pregnancy | 2 | 2023 | 7217 | 0.090 |
Why?
| | Aging | 1 | 2023 | 1983 | 0.090 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 1156 | 0.090 |
Why?
| | Time Factors | 3 | 2019 | 7079 | 0.080 |
Why?
| | Disease Progression | 1 | 2019 | 2857 | 0.080 |
Why?
| | Abortion, Induced | 1 | 2013 | 112 | 0.080 |
Why?
| | Chemical Fractionation | 1 | 2010 | 29 | 0.080 |
Why?
| | Food Analysis | 1 | 2010 | 22 | 0.080 |
Why?
| | Heart Atria | 1 | 2010 | 139 | 0.080 |
Why?
| | Genetic Variation | 1 | 2015 | 992 | 0.070 |
Why?
| | Bacteria | 1 | 2015 | 766 | 0.070 |
Why?
| | Chloramphenicol | 1 | 2008 | 11 | 0.070 |
Why?
| | Risk Factors | 2 | 2024 | 10840 | 0.070 |
Why?
| | Exercise Tolerance | 1 | 2010 | 288 | 0.070 |
Why?
| | China | 2 | 2020 | 278 | 0.070 |
Why?
| | Radiation Protection | 1 | 2008 | 41 | 0.070 |
Why?
| | Lung | 1 | 2021 | 4119 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2218 | 0.060 |
Why?
| | Adult | 6 | 2024 | 40821 | 0.060 |
Why?
| | Radiology, Interventional | 1 | 2008 | 49 | 0.060 |
Why?
| | Biomarkers | 1 | 2019 | 4329 | 0.060 |
Why?
| | Education, Medical, Continuing | 1 | 2008 | 130 | 0.060 |
Why?
| | Prognosis | 3 | 2023 | 4331 | 0.060 |
Why?
| | Apoptosis | 1 | 2015 | 2436 | 0.060 |
Why?
| | Radiation Dosage | 1 | 2008 | 193 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8351 | 0.060 |
Why?
| | Animals | 6 | 2023 | 38030 | 0.050 |
Why?
| | Sphingomyelins | 1 | 2024 | 22 | 0.050 |
Why?
| | Heart Transplantation | 1 | 2010 | 679 | 0.050 |
Why?
| | Purinergic P2X Receptor Antagonists | 1 | 2023 | 7 | 0.050 |
Why?
| | beta-Arrestins | 1 | 2023 | 15 | 0.050 |
Why?
| | Dynamins | 1 | 2023 | 37 | 0.050 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2023 | 24 | 0.050 |
Why?
| | Aggrecans | 1 | 2023 | 15 | 0.050 |
Why?
| | Shellfish | 1 | 2022 | 6 | 0.050 |
Why?
| | Mitochondrial Dynamics | 1 | 2023 | 41 | 0.050 |
Why?
| | Solid Phase Extraction | 1 | 2022 | 28 | 0.050 |
Why?
| | Tetrodotoxin | 1 | 2022 | 40 | 0.050 |
Why?
| | Molecular Docking Simulation | 1 | 2023 | 120 | 0.050 |
Why?
| | Porosity | 1 | 2022 | 95 | 0.050 |
Why?
| | Faculty | 1 | 2023 | 151 | 0.040 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2022 | 39 | 0.040 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2022 | 193 | 0.040 |
Why?
| | PPAR gamma | 1 | 2023 | 180 | 0.040 |
Why?
| | Cholesterol, LDL | 1 | 2024 | 363 | 0.040 |
Why?
| | Carbon | 1 | 2022 | 176 | 0.040 |
Why?
| | Pandemics | 2 | 2020 | 1700 | 0.040 |
Why?
| | Educational Status | 1 | 2023 | 466 | 0.040 |
Why?
| | Microglia | 1 | 2024 | 285 | 0.040 |
Why?
| | Mice | 3 | 2023 | 18266 | 0.040 |
Why?
| | Molecular Sequence Data | 2 | 2015 | 2835 | 0.040 |
Why?
| | Mammals | 1 | 2022 | 287 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2022 | 452 | 0.040 |
Why?
| | Neurogenesis | 1 | 2022 | 158 | 0.040 |
Why?
| | Brain | 2 | 2024 | 2981 | 0.040 |
Why?
| | Inflammation | 2 | 2022 | 2915 | 0.040 |
Why?
| | Molecular Targeted Therapy | 1 | 2023 | 446 | 0.040 |
Why?
| | Pain Management | 1 | 2024 | 413 | 0.040 |
Why?
| | Thorax | 1 | 2020 | 51 | 0.040 |
Why?
| | Pathologists | 1 | 2019 | 19 | 0.040 |
Why?
| | Molecular Structure | 2 | 2013 | 483 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2019 | 23 | 0.040 |
Why?
| | Pediatrics | 1 | 2008 | 1122 | 0.040 |
Why?
| | Multilevel Analysis | 1 | 2019 | 35 | 0.040 |
Why?
| | Autophagy | 1 | 2022 | 290 | 0.040 |
Why?
| | Osmolar Concentration | 2 | 2010 | 165 | 0.040 |
Why?
| | Cloning, Molecular | 1 | 2020 | 526 | 0.040 |
Why?
| | Observer Variation | 1 | 2019 | 355 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 183 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2019 | 275 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 1 | 2020 | 367 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2019 | 303 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2022 | 533 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2010 | 533 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2020 | 3396 | 0.030 |
Why?
| | R Factors | 1 | 2016 | 1 | 0.030 |
Why?
| | Down-Regulation | 1 | 2019 | 612 | 0.030 |
Why?
| | Anxiety | 1 | 2024 | 1118 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2023 | 1367 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1526 | 0.030 |
Why?
| | Up-Regulation | 1 | 2019 | 840 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 119 | 0.030 |
Why?
| | Retrospective Studies | 3 | 2019 | 17291 | 0.030 |
Why?
| | Escherichia coli Infections | 1 | 2016 | 125 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2023 | 3121 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2015 | 109 | 0.030 |
Why?
| | Burns | 1 | 2020 | 365 | 0.030 |
Why?
| | Hypertrophy | 1 | 2015 | 126 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 143 | 0.030 |
Why?
| | Muscular Diseases | 1 | 2015 | 110 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2019 | 1486 | 0.030 |
Why?
| | Caspases | 1 | 2015 | 233 | 0.030 |
Why?
| | Exons | 1 | 2015 | 361 | 0.030 |
Why?
| | Genomics | 1 | 2020 | 851 | 0.030 |
Why?
| | Critical Care | 1 | 2020 | 700 | 0.030 |
Why?
| | Cross Infection | 1 | 2016 | 258 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 2078 | 0.030 |
Why?
| | DNA Primers | 1 | 2015 | 487 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2015 | 505 | 0.020 |
Why?
| | Species Specificity | 1 | 2015 | 542 | 0.020 |
Why?
| | Anions | 1 | 2013 | 29 | 0.020 |
Why?
| | Mifepristone | 1 | 2013 | 45 | 0.020 |
Why?
| | Misoprostol | 1 | 2013 | 15 | 0.020 |
Why?
| | Patient Discharge | 1 | 2020 | 991 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2015 | 494 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 700 | 0.020 |
Why?
| | Neurons | 1 | 2022 | 1663 | 0.020 |
Why?
| | Silver | 1 | 2013 | 35 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1754 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2013 | 139 | 0.020 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 507 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2015 | 610 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2910 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 2015 | 2088 | 0.020 |
Why?
| | Base Sequence | 1 | 2015 | 2119 | 0.020 |
Why?
| | Ethane | 1 | 2010 | 2 | 0.020 |
Why?
| | Hydrocarbons, Chlorinated | 1 | 2010 | 21 | 0.020 |
Why?
| | Pulmonary Ventilation | 1 | 2010 | 80 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2766 | 0.020 |
Why?
| | Sodium Chloride | 1 | 2010 | 138 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 1429 | 0.020 |
Why?
| | Ovarian Neoplasms | 1 | 2015 | 598 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1935 | 0.020 |
Why?
| | Eye Protective Devices | 1 | 2008 | 8 | 0.020 |
Why?
| | Solvents | 1 | 2008 | 112 | 0.020 |
Why?
| | Models, Molecular | 1 | 2013 | 1571 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2497 | 0.020 |
Why?
| | Radiation, Ionizing | 1 | 2008 | 84 | 0.020 |
Why?
| | Exercise Test | 1 | 2010 | 634 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2015 | 3538 | 0.020 |
Why?
| | Fluoroscopy | 1 | 2008 | 177 | 0.020 |
Why?
| | Echocardiography | 1 | 2010 | 645 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2783 | 0.020 |
Why?
| | Radiation Injuries | 1 | 2008 | 149 | 0.020 |
Why?
| | Safety | 1 | 2008 | 346 | 0.010 |
Why?
| | Occupational Exposure | 1 | 2008 | 356 | 0.010 |
Why?
| | Young Adult | 1 | 2013 | 14240 | 0.010 |
Why?
|
|
Ying's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|